Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin,Michael D. Roth,Philip J. Clements,Daniel E. Furst,Dinesh Khanna,Eric C. Kleerup,Jonathan G. Goldin,Edgar Arriola,Elizabeth R. Volkmann,Suzanne Kafaja,Richard M. Silver,Virginia D. Steen,Charlie Strange,Robert A. Wise,Fredrick M. Wigley,Maureen D. Mayes,David J. Riley,Sabiha Hussain,Shervin Assassi,Vivien Hsu,Bela Patel,Kristine Phillips,Fernando J. Martinez,Jeffrey A. Golden,M. Kari Connolly,John Varga,Jane Dematte,Monique Hinchcliff,Aryeh Fischer,Jeffrey J. Swigris,Richard T. Meehan,Arthur C. Theodore,Robert W. Simms,Suncica Volkov,Dean E. Schraufnagel,Mary Beth Scholand,Tracy M. Frech,Jerry A. Molitor,Kristin B. Highland,Charles A. Read,Marvin J. Fritzler,Grace Kim,Chi-Hong Tseng,Robert Elashoff +43 more
TLDR
In this article, the authors used a modified intention-to-treat analysis using an inferential joint model combining a mixed-effects model for longitudinal outcomes and a survival model to handle non-ignorable missing data.About:
This article is published in The Lancet Respiratory Medicine.The article was published on 2016-09-01 and is currently open access. It has received 662 citations till now. The article focuses on the topics: Scleroderma & FEV1/FVC ratio.read more
Citations
More filters
Journal ArticleDOI
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
TL;DR: The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintinganib than with placebo.
Journal ArticleDOI
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Keith M. Sullivan,Ellen Goldmuntz,Lynette Keyes-Elstein,Peter A. McSweeney,Ashley Pinckney,Beverly Welch,Maureen D. Mayes,Richard A. Nash,Leslie J. Crofford,Barry Eggleston,Sharon Castina,Linda M. Griffith,Julia S. Goldstein,Dennis Wallace,Oana Craciunescu,Dinesh Khanna,Rodney J. Folz,Jonathan G. Goldin,E. W. Clair,James R. Seibold,Kristine Phillips,Shin Mineishi,Robert W. Simms,Karen K. Ballen,Mark H. Wener,George E. Georges,Shelly Heimfeld,Chitra Hosing,Stephen J. Forman,Suzanne Kafaja,Richard M. Silver,L. Griffing,Jan Storek,Sharon LeClercq,R. Brasington,Mary Ellen Csuka,Christopher Bredeson,Carolyn A. Keever-Taylor,R.T. Domsic,M. B. Kahaleh,Thomas A. Medsger,Daniel E. Furst,Daniel E. Furst +42 more
TL;DR: Myeloablative autologous hematopoietic stem‐cell transplantation achieved long‐term benefits in patients with scleroderma, including improved event‐free and overall survival, at a cost of increased expected toxicity.
Journal ArticleDOI
Shared and distinct mechanisms of fibrosis
Jörg H W Distler,Andrea-Hermina Györfi,Meera Ramanujam,Michael L. Whitfield,Melanie Königshoff,Melanie Königshoff,Robert Lafyatis +6 more
TL;DR: A number of core pathways and mechanisms of fibrosis, outlined in this Review, are shared across different tissues and might therefore present targets for general antifibrotic strategies and might enable the development of general antIFIBrotic compounds that are effective across different disease entities and organs.
Journal ArticleDOI
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna,Christopher P. Denton,Celia J. F. Lin,Jacob M van Laar,Tracy M. Frech,Marina E Anderson,Murray Baron,Lorinda Chung,Gerhard Fierlbeck,Santhanam Lakshminarayanan,Yannick Allanore,Janet E. Pope,Gabriela Riemekasten,Virginia D. Steen,Ulf Müller-Ladner,Helen Spotswood,Laura Burke,Jeffrey Siegel,Angelika Jahreis,Daniel E. Furst +19 more
TL;DR: Skin score improvement and FVC stabilisation in the double-blind period were observed in placebo-treated patients who transitioned to tocilizumab and were maintained in the open-label period and safety data indicated increased serious infections in patients with SSc but no new safety signals with tocilIZumab.
Journal ArticleDOI
What's in a name? That which we call IPF, by any other name would act the same.
TL;DR: The clinical and pathogenetic justification for a focus on “the progressive fibrotic phenotype” in future clinical and translational research is summarised, to address the needs of non-IPF patients with inexorably progressive Fibrotic disease, currently disenfranchised by lack of access to agents that are efficacious in IPF.
References
More filters
Journal ArticleDOI
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.
TL;DR: In this article, cross-sectional data from the Medical Outcomes Study (MOS) were analyzed to test the validity of the MOS 36-Item Short-Form Health Survey (SF-36) scales as measures of physical and mental health constructs.
Journal ArticleDOI
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
TL;DR: A multicenter, ongoing study of early-diagnosed cases of systemic sclerosis and comparison patients with systemic lupus erythematosus, polymyositis/dermatomyositis, and Raynaud's phenomenon was conducted in order to develop classification criteria for systemic sclerosis.
Journal ArticleDOI
Spirometric Reference Values from a Sample of the General U.S. Population
TL;DR: Hankinson and Odencrantz as mentioned in this paper used a piecewise polynomial model with age and height as predictors to derive reference values for three race/ethnic groups and should prove useful for diagnostic and research purposes.
Journal ArticleDOI
The MOS short-form general health survey. Reliability and validity in a patient population.
Journal Article
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
C Leroy,Roy D. Altman,J.B. Kirsner,Jonathan A. Myers,Dennis J. McShane,D. Masi,Gordon C. Sharp,Gerald P. Rodnan,A. MacKenzie-Graham,Thomas A. Medsger,James F. Fries +10 more
TL;DR: Proposed classification criteria for systemic sclerosis had a 97% sensitivity for definite systemic sclerosis and 98% specificity when applied to the case and comparison patients included in this study.
Related Papers (5)
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Jonathan G. Goldin,Michael D. Roth,Daniel E. Furst,Edgar Arriola,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky +30 more
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more
Interstitial lung disease in systemic sclerosis: a simple staging system.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more